Yifan Pharmaceutical Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 2, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020
Market Capitalization	12,419	13,040	18,014	15,019	21,745	23,372
Market Cap Growth	-3.13%	-27.61%	19.94%	-30.93%	-6.96%	36.83%
Enterprise Value	13,938	14,371	19,400	16,499	22,717	23,710
Last Close Price	11.98	10.63	14.52	12.03	17.31	18.55
PE Ratio	35.26	33.78	-	78.54	78.11	24.14
Forward PE	23.49	20.82	33.59	16.33	32.78	16.68
PS Ratio	2.38	2.53	4.43	3.92	4.93	4.33
PB Ratio	1.43	1.55	2.18	1.64	2.48	2.68
P/TBV Ratio	2.84	3.29	4.67	2.82	4.23	4.70
P/FCF Ratio	-	1037.05	-	-	-	59.50
P/OCF Ratio	20.24	20.35	51.68	31.82	72.19	21.09
PEG Ratio	-	0.21	0.21	0.21	0.21	0.21
EV/Sales Ratio	2.67	2.79	4.77	4.30	5.15	4.39
EV/EBITDA Ratio	17.92	22.36	76.48	43.52	50.06	19.91
EV/EBIT Ratio	35.01	44.07	17820.38	96.29	86.48	23.38
EV/FCF Ratio	-223.08	1142.95	-	-	-	60.36
Debt / Equity Ratio	0.29	0.27	0.24	0.24	0.26	0.19
Debt / EBITDA Ratio	3.24	3.49	7.34	5.44	4.84	1.39
Debt / FCF Ratio	-	182.47	-	-	-	4.23
Asset Turnover	0.41	0.43	0.34	0.31	0.37	0.48
Inventory Turnover	2.36	2.83	2.45	2.65	4.16	4.91
Quick Ratio	0.80	0.84	0.94	1.19	1.13	1.22
Current Ratio	1.27	1.26	1.49	1.68	1.56	1.65
Return on Equity (ROE)	4.39%	3.88%	-10.18%	1.42%	2.77%	11.25%
Return on Assets (ROA)	1.95%	1.71%	0.01%	0.87%	1.38%	5.58%
Return on Invested Capital (ROIC)	3.33%	2.81%	0.01%	1.40%	2.80%	10.17%
Return on Capital Employed (ROCE)	4.10%	3.50%	0.00%	1.70%	2.70%	10.70%
Earnings Yield	3.28%	2.96%	-3.06%	1.27%	1.28%	4.14%
FCF Yield	-0.50%	0.10%	-0.86%	-0.47%	-1.24%	1.68%
Dividend Yield	0.82%	1.88%	-	-	-	0.27%
Payout Ratio	42.85%	50.47%	-	45.18%	49.71%	20.86%
Buyback Yield / Dilution	1.94%	1.51%	3.94%	-5.32%	1.26%	-0.40%
Total Shareholder Return	2.76%	3.39%	3.94%	-5.32%	1.26%	-0.13%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.